Adiponectin, total anti-oxidant status, and high sensitivity C-reactive protein in Indonesian men with metabolic syndrome

  • Cynthia R. Sartika
  • Widjaja Lukito
  • Andi Wijaya
Abstract viewed: 403 times
PDF downloaded: 278 times


Aim: To examine biochemical markers of adiponectin, total anti-oxidant status (TAOS) and high sensitvity C-reactive protein (hsCRP) in individuals with and without metabolic syndrome (MetS).

Methods: A cross-sectional study on 36 non-MetS and 36 MetS  subjects was undertaken in Jakarta. Measured indicators were adiponectin, TAOS and hsCRP, apart from weight, height, waist circumference (WC), systolic blood pressure (SBP), diastolic  blood pressure (DBP), and fasting blood glucose (FBG). Odds ratio (OR) of adiponectin, TAOS and hsCRP were calculated to assess risk for the development of MetS. Median values were determined as cutoffs to define high and low values of each parameter. Relationships between adiponectin, TAOS and hsCRP with WC were analyzed by using Spearman correlation analysis, and the contributions of all indicators to the development of MetS were analyzed by using logistic regression.

Results: Adiponectin dan hsCRP differed signifi cantly between non MetS and MetS subjects (4.2 + 1.4 vs 3.1 + 1.0 ug/mL) dan (0.97 + 0.92 vs 3.35 + 3.43 mg/L) (p < 0.01), but no signifi cant difference was found in TAOS (1.24 + 0.1 vs 1.28 + 0.2 mmol/L). Adiponectin associated negatively with WC (rs=  -0.436; p < 0.01), while TAOS and hsCRP associated positively with WC (rs= 0.286, p = 0.02 and rs= 0.597, p < 0.01). The odds ratios (ORs) of adiponectin and hsCRP for the   development of MetS were 4 (p = 0.01) and ~6,8 (p < 0.01), respectively; while the risk of subjects with adiponectinhs CRP
ratio of ≤ 2.31 to develop MetS was 25 times (p < 0.01) those with adiponectin-hsCRP ratio > 2.31.

Conclusion: The use of adiponectin-hsCRP ratio increases the predictive power for the occurrence of MetS by 4-6 times the predictive power of adiponectin or hsCRP alone. (Med J Indones 2009; 18: 262-8)

Keywords: adiponectin, hsCRP, total anti-oxidant status, metabolic syndrome.


  1. Furukawa S, Fujita T, Shimabukuro M. Increased oxidative

  2. stress in obesity and its impact on metabolic syndrome. J

  3. Clin Invest 2004;114:1752–61.

  4. Semadji, G. The prevalence of the metabolic syndrome:

  5. Findings from the epidemiological study on obesity and its co-morbidities in Indonesian population. The 3rd National

  6. Obesity Symposium. Jakarta: Indonesian Society for the

  7. Study on Obesity, 2004.

  8. Grundy S. Metabolic syndrome scientifi c statement by

  9. the American Heart Association and the National Heart,

  10. Lung, and Blood Institute. Arterioscler Thromb Vasc Biol

  11. ;25:2243–4.

  12. Stern PM, Williams K, Gonzales-Villalpando C, Hunt

  13. JK, Haffner SM. Does the metabolic syndrome improve

  14. identifi cation of individuals at risk of type 2 diabetes and/or

  15. cardiovascular disease? Diab Care 2004;27:2676-81.

  16. Sonnenberg GE, Krakower GR, Kissebah AH. A novel

  17. pathway to the manifestations of metabolic syndrome.

  18. Obes Res 2004;12:180–6.

  19. Reilly MP, Rader DJ. The Metabolic syndrome: more than

  20. the sum of its part? Circulation 2003;108:1546-51.

  21. Verma S, Buchanan MR, Anderson T. Endothelial function

  22. testing as a biomarker of vascular disease. Circulation

  23. ;108:2054-9.

  24. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y. Walsh

  25. K. Reciprocal association of C-reactive protein with

  26. adiponectin in blood stream and adipose tissue. Circulation

  27. ;107:671-4.

  28. Ceriello A, Motz E. Is oxidative stress the pathogenic

  29. mechanism underlying insulin resistance, diabetes, and

  30. cardiovascular disease? The common soil hypothesis

  31. revisited. Arterioscler Thromb Vasc Biol 2004;24:816-23.

  32. Xydakis, AM., Case, CC., Jones, PH., Hoogeveen, RC.,

  33. Liu, M-Y., Smith, EO., Nelson, KW. and Ballantyne,

  34. CM. Adiponectin, infl ammation, and the expression of

  35. the metabolic syndrome in obese individuals: The impact

  36. of rapid weight loss through caloric restriction. J Clin

  37. Endocrinol Metab 2004;89:2697-703.

  38. Alberti KG, Zimmet P, Shaw J. IDF epidemiology task

  39. force consensus group: The metabolic syndrome: a new

  40. worldwide defi nition. Lancet 2005;366:1059–62.

  41. Mojiminiyi OA, Abdella NA, Al Arouj M, Nakhi AB.

  42. Adiponectin, insulin resistance and clinical expression of

  43. the metabolic syndrome in patients with type 2 diabetes. Int

  44. J Obes 2007;31:213–20

  45. Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel

  46. PJ, Jialal I. CRP and adiponectin and its oligomers in the

  47. metabolic syndrome: Evaluation of new laboratory-based

  48. biomarkers. Am J Clin Pathol 2008;129:815–22.

  49. Cao G, Prior RL. Comparison of different analytical

  50. methods for assessing total antioxidant capacity of human

  51. serum. Clin Chem 1998;44:1309–15.

  52. Koracevic D, Koracevic G, Djordjevic V, Andredjevic S,

  53. Cosic V. Method for measurement of antioxidant activity in

  54. human fl uids. J Clin Pathol 2001;54:356-61.

  55. Psotová J, Zahálková J, HrbÃ¡Ä J, Å imánek V, Bartek J.

  56. Determination of total antioxidant capacity in plasma by

  57. cyclic voltammetry. two case reports. Biomed Papers

  58. ;145:81–3.

  59. Wang CC, Chu CY, Chu KO, Choy KW, Khaw KS, Rogers

  60. MS, et al. Trolox-equivalent antioxidant capacity assay

  61. versus oxygen radical absorbance capacity assay in plasma.

  62. Clin Chem 2004;50:952-4.

  63. Szmitko PE, Wang C-H, Weisel RD, Almeida JR, Anderson

  64. TJ, Verma S. New marker of infl ammation and endothelial

  65. cell activation: Part I. Circulation 2003;108:1917-23.

How to Cite
Sartika CR, Lukito W, Wijaya A. Adiponectin, total anti-oxidant status, and high sensitivity C-reactive protein in Indonesian men with metabolic syndrome. Med J Indones [Internet]. 2009Nov.1 [cited 2020Sep.22];18(4):262-8. Available from:
Clinical Research

Most read articles by the same author(s)